EYP-1901 not checked
EyePoint Pharmaceuticals, Inc.
FollowEvery change as it happens, and a Monday email
Trials
4 active
8 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Wet Age Related Macular Degeneration (2 trials), wAMD (2 trials), Diabetic Macular Edema (2 trials), DME (2 trials), Diabetic Macular Edema (DME) (2 trials)
- Main trialPhase 3
- “This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.”In the company’s words, NCT06668064 on ClinicalTrials.gov
- Other names
- Vorolanib
Other drugs for Wet Age Related Macular Degeneration
- Surabgene LomparvovecAbbVie · Phase 3
- 4D-150 IVT4D Molecular Therapeutics · Phase 3
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- ElamipretideStealth BioTherapeutics Inc. · Phase 3
- ONS-5010Outlook Therapeutics, Inc. · Phase 3
Coming up2
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovCompletion date moved: 2026-10 to 2026-09-09 · ClinicalTrials.gov NCT06683742
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 13 Jul 2026 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | |
| Phase 3Active, not recruiting | 9 Sep 2026 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | |
| Phase 3Active, not recruiting | Oct 2027 | COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | |
| Phase 3Active, not recruiting | Oct 2027 | CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | |
| Phase 2Completed | 29 Nov 2023 | Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) | |
| Phase 2Completed | 12 Feb 2024 | Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) | |
| Phase 2Completed | 24 Oct 2024 | Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) | |
| Phase 1Completed | 11 May 2022 | First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026